Feeds:
Posts
Comments

Search Results for 'Serotonin'


Acute Changes in Serotonin Detected by AI-designed Serotonin Sensor Reporter: Adina Hazan, PhD   With 14 receptors and expression in central and peripheral nervous system, serotonin is an essential modulatory molecule. It plays critical roles in a multitude of functions, including addiction, appetite, blood pressure, digestion, and sleep. The clinical implications of this is clearly […]

Read Full Post »


Not Lower Levels of Serotonin, but Damaged Brain Synapses as the Origin for Mental Depression Reporter: Aviva Lev-Ari, PhD, RN Israeli discovery matches right antidepressant for each patient Genetic study suggest that depression may be caused not by lack of serotonin, but because of damage to the brain synapses. It all comes down to a […]

Read Full Post »


Recent progress in neurodegenerative diseases and gliomas Curator: Larry H. Bernstein, MD, FCAP LPBI     Alzheimer’s Protein Not All Bad, Says MassGen Study A controversial idea—that amyloid-beta (Aβ) protein fights bacterial infections in the brain—has gained additional support from a new study. Previously, the idea seemed worthy of investigation, if a bit of a […]

Read Full Post »


Neuroscience impact of synaptic pruning discovery Larry H. Bernstein, MD, FCAP, Curator LPBI   Synaptic Pruning Discovery May Lead to New Therapies for Neuro Disorders GEN 3 May, 2016    http://www.genengnews.com/gen-news-highlights/synaptic-pruning-discovery-may-lead-to-new-therapies-for-neuro-disorders/81252680/ Source: NIH      http://www.genengnews.com/Media/images/GENHighlight/thumb_May3_2016_NIH_CRANPuzzleBrain_AdolescentBrain2247219834.jpg   A research team led by scientists at SUNY Downstate Medical Center has identified a brain receptor that appears […]

Read Full Post »


Reversal of Alzheimer Disease in Fruit Flies Curator: Larry H. Bernstein, MD, FCAP     Reversal of AD in fruit flies Transatlantic team reverses Alzheimer’s, Parkinson’s symptoms in fruit flies by Amirah Al Idrus | Apr 26, 2016 http://www.fiercebiotech.com/research/transatlantic-team-reverses-alzheimer-s-parkinson-s-symptoms-fruit-flies Scientists from the University of Leicester and the University of Maryland have reversed Alzheimer’s and Parkinson’s symptoms by inhibiting […]

Read Full Post »


Brain Matters from iBiology Larry H. Bernstein, MD, FCAP, Curator LPBI   ADAM COHEN: VISUALIZING ACTIVITY IN THE BRAIN http://www.ibiology.org/ibiomagazine/adam-cohen-visualizing-activity-brain.html The pattern of electrical signals propagated through neuronal networks determines brain function. Adam Cohen examines the possibility of visualizing these signals inside an intact brain using fluorescent transmembrane proteins that are sensitive to voltage. Cohen […]

Read Full Post »


Schizophrenia genomics Larry H. Bernstein, MD, FCAP, Curator LPBI   Histone Methylation at H3K9; Evidence for a Restrictive Epigenome in Schizophrenia Kayla A. Chase,1David P. Gavin,1Alessandro Guidotti,1 and Rajiv P. Sharma1 Schizophr Res. 2013 Sep; 149(0): 15–20.      doi:  10.1016/j.schres.2013.06.021 Epigenetic changes are stable and long-lasting chromatin modifications that regulate genomewide and local gene activity. […]

Read Full Post »


Dopamine-β-Hydroxylase Functional Variants Curator: Larry H. Bernstein, MD, FCAP     Deep sequencing identifies novel regulatory variants in the distal promoter region of the dopamine-β-hydroxylase gene. Punchaichira TJ1, Prasad S, Deshpande SN, Thelma BK. Pharmacogenet Genomics. 2016 Mar 9     http://www.ncbi.nlm.nih.gov/pubmed/26959714 OBJECTIVE: Dopamine-β-hydroxylase (DBH), an enzyme that converts dopamine into norepinephrine, is a drug target […]

Read Full Post »


AGENDA for Oligonucleotide Therapeutics and Delivery, April 4-5, 2016, HYATT Hotel, Cambridge, MA Reporter: Aviva Lev-Ari, PhD, RN     Oligonucleotide Therapeutics and Delivery   http://www.healthtech.com/oligonucleotide/   Register by January 8 and save up to $350 Oligonucleotide–based therapeutics have long formed the third major drug development platform, specifically focused on modulating gene expression by targeting […]

Read Full Post »


FDAnews Drug Daily Bulletin Pharmaceuticals / Submissions and Approvals Teva Wins Breakthrough Therapy Designation for Tardive Dyskinesia Candidate Nov. 16, 2015 Teva Pharmaceutical Industries has won the FDA’s breakthrough therapy designation for SD-809 for the treatment of moderate to severe tardive dyskinesia. An oral, small molecule inhibitor of vesicular monoamine 2 transporter, SD-809 (deutetrabenazine) is […]

Read Full Post »

Next »